학술논문
Corrigendum to “De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel”: [Annals of Oncology 28 (2017) 2768-2772]
Document Type
Erratum
Author
Source
In Annals of Oncology March 2022 33(3):355-355
Subject
Language
ISSN
0923-7534